All In Biotech

Drug Trial Radar · NCT02029495

Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-1

Last checked: Nov 20, 2026Latest source record: May 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 478 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

478

Actual

Start

Mar 2014

Primary completion

Oct 2015

Study completion Oct 2015

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Jan 8, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis.

Conditions

  • Psoriatic Arthritis

Interventions

  • 210 mg brodalumabDrug

    210 mg brodalumab administered via subcutaneous injection

  • 140 mg brodalumabDrug

    140 mg brodalumab administered via subcutaneous injection

  • PlaceboDrug

    Placebo administered via subcutaneous injection until week 24.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. American College of Rheumatology (ACR) 20 ResponseTime frame: 16 weeks

Locations

152 sites in 17 countries. Site status is shown where the registry gives one.

  • Research Site

    Huntsville, Alabama

  • Research Site

    Tuscaloosa, Alabama

  • Research Site

    Peoria, Arizona

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Los Angeles, California

  • Research Site

    Mather, California

  • Research Site

    Murrieta, California

  • Research Site

    Palm Desert, California

  • Research Site

    Tustin, California

  • Research Site

    Upland, California

  • Research Site

    Jupiter, Florida

  • Research Site

    Tamarac, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Gainesville, Georgia

  • Research Site

    Meridian, Idaho

  • Research Site

    Springfield, Illinois

  • Research Site

    Bowling Green, Kentucky

  • Research Site

    Somerset, Kentucky

  • Research Site

    Frederick, Maryland

  • Research Site

    Wheaton, Maryland

  • Research Site

    Worcester, Massachusetts

  • Research Site

    Lansing, Michigan

  • Research Site

    Eagan, Minnesota

  • Research Site

    Omaha, Nebraska

  • Research Site

    Clifton, New Jersey

  • Research Site

    Great Neck, New York

  • Research Site

    Lake Success, New York

  • Research Site

    New York, New York

  • Research Site

    Plainview, New York

  • Research Site

    Asheville, North Carolina

  • Research Site

    Bend, Oregon

  • Research Site

    Portland, Oregon

  • Research Site

    Duncansville, Pennsylvania

  • Research Site

    Charleston, South Carolina

  • Research Site

    Hixson, Tennessee

  • Research Site

    Austin, Texas

  • Research Site

    Houston, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Danville, Virginia

  • Research Site

    Seattle, Washington

Showing 40 of 152 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.